Magellan Health market cap is $2.5 b, and annual revenue was $4.58 b in FY 2020

Magellan Health Gross profit (Q1, 2021)290.1 M

Magellan Health Gross profit margin (Q1, 2021), %25%

Magellan Health Net income (Q1, 2021)27.8 M

Magellan Health Cash, 31-Mar-2021456.3 M

Magellan Health EV2.6 B

Magellan Health revenue was $4.58 b in FY, 2020 which is a 36.1% year over year decrease from the previous period.

Magellan Health revenue breakdown by business segment: 49.2% from Managed care and other and 50.8% from Pharmacy Benefit Management

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Revenue | 7.3b | 7.2b | 4.6b |

| (2%) | (36%) | |

## Cost of goods sold | 6.0b | 5.8b | 3.6b |

## Gross profit | 1.3b | 1.3b | 999.0m |

| 17% | 18% | 22% |

## Operating expense total | 1.2b | 1.2b | 978.6m |

## Depreciation and amortization | 132.7m | 131.5m | 98.4m |

## Interest expense | 35.4m | 36.2m | 30.9m |

## Interest income | 14.1m | 19.2m | 4.1m |

## Pre tax profit | 43.2m | 80.8m | (40.5m) |

## Income tax expense | 19.0m | 24.9m | (44.5m) |

## Net Income | 24.2m | 55.9m | 382.3m |

## EPS | 1.0 | 2.3 | 15.0 |

USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|

## Revenue | 1.7b | 1.8b | 1.8b | 1.8b | 1.1b | 1.2b | 1.2b |

## Cost of goods sold | 1.4b | 1.5b | 1.5b | 1.4b | 849.9m | 924.7m | 871.6m |

## Gross profit | 307.7m | 325.3m | 333.7m | 356.5m | 250.2m | 245.4m | 290.1m |

| 18% | 18% | 18% | 20% | 23% | 21% | 25% |

## Operating expense total | 302.6m | 299.9m | 300.5m | 316.4m | 223.6m | 241.5m | 252.4m |

## Depreciation and amortization | 30.7m | 33.5m | 34.2m | 28.7m | 23.9m | 24.7m | 21.4m |

## Interest expense | 9.1m | 9.1m | 9.0m | 9.0m | 8.0m | 7.3m | 6.4m |

## Interest income | 5.0m | 5.0m | 5.0m | 3.8m | 551.0k | 349.0k | 341.0k |

## Pre tax profit | 970.0k | 21.2m | 29.1m | 34.8m | 10.8m | (19.6m) | 39.4m |

## Income tax expense | 539.0k | 7.6m | 7.9m | 16.6m | (36.3m) | (2.3m) | 10.9m |

## Net Income | 431.0k | 13.6m | 21.3m | 18.3m | 83.5m | 11.6m | 27.8m |

## EPS | 0.0 | 0.6 | 0.9 | 0.7 | 3.3 | 0.5 | 1.0 |

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Cash | 272.3m | 325.2m | 1.1b |

## Accounts Receivable | 756.1m | 890.1m | 743.5m |

## Inventories | 40.8m | 45.0m | 43.3m |

## Current Assets | 1.5b | 1.7b | 2.2b |

## PP&E | 150.7m | 138.4m | 136.7m |

## Goodwill | 1.0b | 1.0b | 873.8m |

## Total Assets | 3.0b | 3.1b | 3.4b |

## Accounts Payable | 72.1m | 88.4m | 137.4m |

## Short-term debt | 24.3m | 3.5m | 6.5m |

## Current Liabilities | 898.9m | 910.1m | 737.6m |

## Long-term debt | 728.6m | 679.1m | 631.9m |

## Total Debt | 752.9m | 682.6m | 638.4m |

## Total Liabilities | 1.7b | 1.7b | 1.5b |

## Common Stock | 535.0k | 543.0k | 555.0k |

## Additional Paid-in Capital | 1.3b | 1.4b | 1.5b |

## Retained Earnings | 1.4b | 1.5b | 1.9b |

## Total Equity | 1.3b | 1.4b | 1.9b |

## Debt to Equity Ratio | 0.6 x | 0.5 x | 0.3 x |

## Debt to Assets Ratio | 0.3 x | 0.2 x | 0.2 x |

## Financial Leverage | 2.3 x | 2.2 x | 1.8 x |

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Net Income | 24.2m | 55.9m | 382.3m |

## Depreciation and Amortization | 132.7m | 131.5m | 118.7m |

## Accounts Receivable | (99.3m) | (134.0m) | 17.1m |

## Inventories | 127.0k | (4.1m) | 1.6m |

## Accounts Payable | 9.1m | 56.8m | 225.1m |

## Cash From Operating Activities | 164.8m | 115.8m | 450.8m |

## Purchases of PP&E | (68.3m) | (60.4m) | (75.5m) |

## Cash From Investing Activities | (128.4m) | (19.5m) | 678.9m |

## Long-term Borrowings | (122.2m) | (67.5m) | (131.7m) |

## Cash From Financing Activities | (162.8m) | (43.4m) | 13.1m |

## Net Change in Cash | (126.4m) | 52.9m | 1.0b |

USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|

## Net Income | 431.0k | 14.0m | 35.3m | 18.3m | 101.8m | 113.4m | 27.8m |

## Depreciation and Amortization | 30.7m | 64.2m | 98.4m | 28.7m | 58.0m | 88.1m | 21.4m |

## Accounts Receivable | (23.8m) | (51.5m) | (54.3m) | (33.3m) | (24.5m) | (78.7m) | (50.0m) |

## Inventories | (6.3m) | (4.8m) | (7.6m) | 2.6m | 8.3m | 7.3m | (3.1m) |

## Accounts Payable | 20.4m | 20.8m | 84.0m | 52.7m | 63.0m | 110.7m | (76.2m) |

## Cash From Operating Activities | 35.4m | 29.4m | 144.4m | 31.7m | 170.8m | 232.0m | (77.9m) |

## Purchases of PP&E | (12.6m) | (27.8m) | (44.2m) | (15.7m) | (38.3m) | (56.0m) | (19.5m) |

## Cash From Investing Activities | (57.0m) | (35.6m) | (1.1m) | (28.0m) | (168.2m) | (218.4m) | (509.5m) |

## Long-term Borrowings | (7.3m) | (15.5m) | (50.9m) | (34.8m) | (40.3m) | (126.1m) | (105.5m) |

## Cash From Financing Activities | (17.4m) | (5.7m) | (38.9m) | 55.0m | 68.4m | 3.1m | (100.8m) |

## Net Change in Cash | (38.9m) | (12.0m) | 104.4m | 58.7m | 44.7m | 36.3m | (688.1m) |

USD | FY, 2018 |
---|---|

## EV/CFO | 11.2 x |

## Revenue/Employee | 696.6k |

## Debt/Equity | 0.6 x |

## Debt/Assets | 0.3 x |

## Financial Leverage | 2.3 x |

## P/E Ratio | 58.6 |

Q1, 2018 | Q2, 2018 | Q3, 2018 | FY, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | FY, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | FY, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Offices | 68 | 55 | 49 | |||||||||

## Office Space, sq. ft. | 1.1 m | 948 k | 886 k | |||||||||

## Customers (Healthcare Providers) | 220 k | 265 k | 170 k | |||||||||

## Adjusted Claims | 25.64 k | 50.61 k | 75.8 k | 101.75 k | 26.71 k | 53.41 k | 80.16 k | 106.8 k | 24.57 k | 46.19 k | 60.37 k | 81.24 k |

## Commercial Network Claims | 7.55 k | 15.1 k | 22.8 k | 31.32 k | 6.85 k | 13.9 k | 20.81 k | 28 k | 6.74 k | 11.66 k | 20.77 k | 27.98 k |

## Commercial PBM Covered Lives | 2.02 k | 2.04 k | 2.05 k | 1.99 k | 1.91 k | 1.86 k | 1.79 k | 1.66 k | 1.76 k | 1.88 k | 1.87 k | 1.9 k |

## Medical Pharmacy Covered Lives | 13.87 k | 13.73 k | 13.99 k | 13.91 k | 13.94 k | 12.57 k | 14 k | 13.99 k | 16.05 k | 15.83 k | 15.9 k | 15.77 k |

## PBA Claims | 18.09 k | 35.52 k | 53.01 k | 70.43 k | 19.87 k | 39.51 k | 59.35 k | 78.8 k | 17.83 k | 34.53 k | 39.6 k | 53.26 k |

FY, 2020 | |
---|---|

Male (Leadership), percent | 20.5% |

Female (Leadership), percent | 29.5% |

Male, percent | 13% |

Female, percent | 37% |

- Source: www.sec.gov